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Foreword
Prevention through vaccination: expanding pneumococcal
vaccine coverage and valency
The 7-valent pneumococcal conjugate vaccine (PCV7) has had
a dramatic impact on the epidemiology of pneumococcal disease
worldwide. PCV7 has proven efﬁcacy and documented clinical
effectiveness against invasive pneumococcal disease, pneumonia,
and otitis media caused by the 7 serotypes included in the vaccine
(4, 6B, 9V, 14, 18C, 19F, and 23F).Withmillions of doses distributed
worldwide, PCV7 has a well-established safety proﬁle, with over a
decade of pre- and postlicensure experience. The vaccine has been
incorporated into the national immunization programs of more
than 40 countries and can be administered in 2+1 or 3+1 dosing
schedules concomitantly with other routine pediatric vaccines.
PCV7 has not only reduced the incidence of pneumococcal disease
worldwide, it has also reduced associated hospitalizations and
medical visits, antibiotic use, antibiotic resistance, and nasopha-
ryngeal carriage of the vaccine serotypes, making it a cost-effective
medical intervention.
Despite the widespread and favorable impact of PCV7 on
pneumococcal disease among infants, children, and adults, disease
caused by nonvaccine serotypes continues to be a signiﬁcant public
health concern. Two expanded-valency pneumococcal conjugate
vaccines—13-valent and 10-valent—have been approved recently
inmultiple countriesworldwide. The13-valent pneumococcal con-
jugate vaccine (PCV13), which contains 6 additional serotypes—1,
3, 5, 6A, 7F, and 19A—has been evaluated in comparison with
PCV7 in the context of World Health Organization (WHO) licensing
criteria. PCV13 has been found to meet the WHO licensing criteria
of immunologic noninferiority (compared with PCV7), safety,
and compatibility with concomitant vaccines. The 10-valent
pneumococcal polysaccharide vaccine conjugated to protein D
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derived from nontypeable Haemophilus inﬂuenzae contains an
additional 3 serotypes not covered by PCV7—1, 5, and 7F. Although
a potential beneﬁt of the 10-valent pneumococcal conjugate
vaccine (PCV10) is coverage of nontypeable strains of H inﬂuenzae,
the vaccine does not cover serotypes 3, 6A, or 19A—strains that are
recognized increasingly as causative pathogens and/or antibiotic
resistant. PCV10 has been found to be comparable to PCV7 in terms
of immunogenicity, safety, reactogenicity, and compatibility with
major childhood vaccines.
Vaccine coverage in developing nations continues to lag behind
coverage in developed nations, which may account for the wide
disparity between developing and industrialized nations with
respect to the incidence of pediatric pneumococcal disease and its
associated mortality rate. Expanded-valency vaccines and other
approaches to improve vaccine effectiveness, particularly in the
developing world, were 2 of the important issues discussed at the
6th World Congress of the World Society for Pediatric Infectious
Diseases (WSPID) held in Buenos Aires, Argentina, November 19 to
22, 2009. This publication reports the highlights of these and other
discussions on pneumococcal disease and immunization held at
the WSPID 2009 annual meeting.
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